Home › Trials › NCT04274283

Improving glioma diagnosis and treatment through molecular analysis

A British Feasibility Study of Molecular Stratification and Targeted Therapy to Optimize the Clinical Management of Patients With Glioma by Enhancing Clinical Outcomes, Reducing Avoidable Toxicity, Improving Management of Post-operative Residual & Recurrent Disease and Improving Survivorship

Observational University of Birmingham · NCT04274283

This study is trying to improve how gliomas are diagnosed and treated by looking at the genetic changes in tumors to find better, personalized therapies for patients.

Quick facts

Study typeObservational
Enrollment1000 (estimated)
Ages16 Years and up
SexAll
SponsorUniversity of Birmingham Academic / other
Drugs / interventionschemotherapy
Locations14 sites (Birmingham and 13 other locations)
Trial IDNCT04274283 on ClinicalTrials.gov

What this trial studies

The Tessa Jowell BRAIN MATRIX - Platform Study aims to enhance the precision of glioma diagnosis by establishing a network of clinical hubs across the UK that specialize in brain tumor management. This initiative focuses on developing the infrastructure necessary for rapid and accurate molecular diagnosis of gliomas, which are challenging to treat due to their complex nature. By analyzing the genetic changes in tumors, the study seeks to identify targeted therapies that could improve patient outcomes. Ultimately, this platform will facilitate the introduction of clinical trials for tailored treatments based on individual tumor profiles.

Who should consider this trial

Good fit: Ideal candidates for this study are patients with newly diagnosed or progressing WHO Grade 2-4 gliomas who are suitable for surgical procedures that allow for tumor and blood sample collection.

Not a fit: Patients with primary spinal cord tumors or those undergoing active treatment for other malignancies may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more accurate diagnoses and personalized treatment options for patients with gliomas, potentially improving survival rates and quality of life.

How similar studies have performed: Other studies focusing on molecular diagnostics and targeted therapies for gliomas have shown promise, indicating that this approach is both relevant and potentially impactful.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Newly diagnosed suspected WHO Grade 2-4 glioma, (as evidenced radiologically) AND suitable for a diagnostic or therapeutic surgical procedure resulting in a tumour sample matched to a blood sample.
* Patients with progression with known WHO Grade 2-4 glioma (those with available frozen tumour will be prioritised for detailed genomic analysis).
* Valid written informed consent for the study.

Exclusion Criteria:

* Primary spinal cord tumours
* Active treatment of other malignancy
* Contraindication to MRI
* Patients without standard of care imaging available

Where this trial is running

Birmingham and 13 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Glioma
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.